Cara Therapeutics Inc stock page - price, fundamentals, dividends - iOCharts

CARA

13.34
-0.10 (-0.74%)
Cara Therapeutics Inc (NASDAQ, USD)
Healthcare >
Biotechnology
Market cap
668.20M
Ent value
663.85M
Price/Sales
4.95
Price/Book
3.28
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
79.45
Forward P/E
-
PEG
-
EPS growth
-24.10%
1 year return
-12.01%
3 year return
-10.46%
5 year return
6.36%
10 year return
-
Last updated: 2021-11-26

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open13.26
Daily high13.46
Daily low13.07
Daily Volume516K
All-time high29.19
1y analyst estimate26.00
Beta1.09
EPS (TTM)0.17
Dividend per share-
Ex-div date-
Next earnings date8 Nov 2021

Downside potential

Loading...
Downside potential data
CARAS&P500
Current price drop from All-time high-54.30%-0.06%
Highest price drop-80.50%-56.47%
Date of highest drop27 Jun 20169 Mar 2009
Avg drop from high-42.50%-11.41%
Avg time to new high104 days12 days
Max time to new high948 days1805 days

DIVIDENDS

CARA does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E79.45
Price to OCF-
Price to FCF-
Price to EBITDA84.28
EV to EBITDA83.74

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales4.95
Price to Book3.28
EV to Sales4.91

FINANCIALS

Per share

Loading...
Per share data
Current share count50.09M
EPS (TTM)0.17
FCF per share (TTM)-0.12

Income statement

Loading...
Income statement data
Revenue (TTM)135.08M
Gross profit (TTM)135.08M
Operating income (TTM)5.38M
Net income (TTM)8.41M
EPS (TTM)0.17
EPS (1y forward)-1.38

Margins

Loading...
Margins data
Gross margin (TTM)100.00%
Operating margin (TTM)3.99%
Profit margin (TTM)6.23%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash22.34M
Net receivables1.00M
Total current assets164.47M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment4.36M
Total assets221.45M
Accounts payable13.49M
Short/Current long term debt4.50M
Total current liabilities15.17M
Total liabilities17.99M
Shareholder's equity203.47M
Net tangible assets203.47M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-5.49M
Capital expenditures (TTM)713.00K
Free cash flow (TTM)-6.20M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity3.38%
Return on Assets3.10%
Return on Invested Capital3.38%
Cash Return on Invested Capital-2.49%
COMPANY DETAILS
CARA (Cara Therapeutics Inc) company logo
Marketcap
668.20M
Marketcap category
Small-cap
Description
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Employees
80
SEC filings
CEO
Derek Chalmers
Country
USA
City
Stamford
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
STAMFORD, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company focused on developing and commercializing new chemical en...
November 18, 2021
Jeffrey Ives, Insider at Cara Therapeutics (NASDAQ:CARA), made a large insider sell on November 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange ...
November 17, 2021
STAMFORD, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allev...
November 9, 2021
Please be advised that this call is being recorded at Cara's request. This is Will Gramig with Stern Investor Relations, and welcome to Cara Therapeutics' third quarter 2021 financial results and upd...
November 9, 2021
Cara (CARA) delivered earnings and revenue surprises of 94.44% and 28.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
November 8, 2021
– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administrat...
November 8, 2021
Current Cara director and accomplished commercial dermatology executive, Christopher Posner, appointed as new President and Chief Executive Officer as Company prepares to launch KORSUVA™ (difelikefali...
November 3, 2021
Investors hungry for stocks that can make big moves in a short amount of time know the biotech industry is the best place to look. A new drug approval, or simply clinical trial results that suggest s...
November 3, 2021
STAMFORD, Conn., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to allev...
November 1, 2021
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
November 1, 2021
Next page